May 30th 2009 | Impact of psoriasis, Patient Stories | 0 Comments
Because many cases of psoriasis are (thankfully) mild, people can sometimes not realize how severe psoriasis can get. Cindy, a young woman who was just released from the hospital for psoriasis treatment, has given us permission to post this slide show, which was made this past week by the love of her life, Fred.
READ THE FULL POST
May 30th 2009 | Impact of psoriasis, Psoriasis Research | 0 Comments
A new study published in the Archives of Dermatology provided further evidence of a link between psoriasis, diabetes and hypertension. Researchers from Harvard Medical School and Brigham Women’s Hospital in Boston concluded “psoriasis was independently associated with an increased risk of diabetes and hypertension.”
78,061 female nurses aged 27 to 44 were studied (none had diabetes
READ THE FULL POST
May 29th 2009 | Psoriasis Research, Treatment | 0 Comments
Cyclosporine is a powerful immune suppressant that is very effective in treating serious psoriasis, but its side-effects (most commonly, kidney damage, and the increased potential for cancers), limits its use in psoriasis to relatively short bursts of time (generally no more than 1-2 years). Cyclosporine is a type of immune suppressant called a calcineurin
READ THE FULL POST
May 26th 2009 | Biologics, Psoriasis Research | 0 Comments
The US Food and Drug Administration (FDA) has extended its time-frame for review of the promising new biologic Stelara (ustekinumab) for moderate to severe psoriasis by 90 days. That would mean we can expect a decision about Stelara by the fall of 2009. Stelara has already been approved for use in Canada.
May 26th 2009 | Patient Stories | 0 Comments
Did we forget to plug Jen’s Psoriasis Patient Calendar profile? You should check it out.
Jen has had psoriasis as long as she can remember, which might explain why she hopes to become a nurse specializing in dermatology.
May 26th 2009 | Biologics, Treatment, psoriatic arthritis | 0 Comments
On April 24, the U.S. Food and Drug Administration (FDA) approved Simponi (golimumab) for the treatment of three forms of arthritis, including active psoriatic arthritis. Described in media reports as a “potential blockbuster drug,” Simponi is administered once monthly via injection under the skin. As WebMD put it: “Simponi is in a
READ THE FULL POST
